Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1465854 | 0.81 | CYP2A6 (0.53) | LOXL2HRH4RAB9ANPC1KDM4E | |
| SCHEMBL12827223 | 0.78 | KDM4E (0.41) | DAORAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL1465481 | 0.76 | CYP19A1 (0.51) | CA12CA9HRH4KDM4EALDH1A1 | |
| SCHEMBL75581 | 0.70 | CYP2A6 (0.63) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL29727931 | 0.70 | CYP2A6 (0.63) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL4258126 | 0.68 | CHEK1 (0.39) | — | |
| SCHEMBL130537 | 0.67 | LOXL2 (0.58) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL13856773 | 0.67 | LOXL2 (0.53) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL9852611 | 0.67 | DAO (0.61) | LOXL2PIN1DAOCA12CA9 | |
| SCHEMBL10181131 | 0.67 | LOXL2 (0.53) | LOXL2PIN1DAOCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-22 | — | — | US | disclosed |
| US-20150174098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150094304-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMA (US) | 2015-04-02 | — | — | US | disclosed |
| US-8952049-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952050-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623905-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8575209-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vextex Pharmaceuticals Incorporated (US) | 2013-07-11 | — | — | US | disclosed |
| US-8415387-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174098-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
| US-20150094304-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
| US-20160271105-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | LOXL2 3949/4885PIN1 3215/4885DAO 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.